Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;5(3):142-7.
doi: 10.4306/pi.2008.5.3.142. Epub 2008 Sep 30.

Triple reuptake inhibitors: a premise and promise

David M Marks  1 , Chi-Un Pae, Ashwin A Patkar
Affiliations

Triple reuptake inhibitors: a premise and promise

David M Marks et al. Psychiatry Investig. 2008 Sep.

Abstract

On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these drugs. Research suggests that they may have a role in treating depressive disorders, and it is plausible they may have potential efficacy in obesity, addiction, and pain syndromes. The current review describes some of the molecules in development presently and explores the research relevant to possible clinical uses for this class of medications.

Keywords: Dopamine; Norephinephrine; Serotonin; Triple reuptake inhibitor.

PubMed Disclaimer

References

    1. Frantz S. Drug discovery: playing dirty. Nature. 2005;437:942–943. - PubMed
    1. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;6:10–18. - PubMed
    1. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry. 2004;65(suppl 17):5–10. - PubMed
    1. Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, et al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol. 2007;555:30–36. - PubMed
    1. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc. 2001;76:511–527. - PubMed

LinkOut - more resources